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Aims To determine independent associations of diabetes mellitus with outcomes in a propensity-matched cohort of
patients with acute myocardial infarction (AMI) and systolic heart failure (HF).
Methods
and results
In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) trial, hos-
pitalized AMI patients complicated by left ventricular ejection fraction ≤40% and symptoms of HF receiving standard
therapy were randomized 3–14 days post-AMI to receive eplerenone 25–50 mg/day (n ¼ 3319) or placebo
(n ¼ 3313). Of the 6632 patients, 2142 (32%) had a history of diabetes, who were older and sicker. Using propensity
scores for diabetes, we assembled a cohort of 1119 pairs of patients with and without diabetes who were balanced
on 64 baseline characteristics. Incident fatal or nonfatal recurrent AMI occurred in 136 (12%) and 87 (8%) of matched
patients with and without diabetes, respectively, during 2.5 years of follow-up [hazard ratio (HR) when diabetes was
compared with no-diabetes, 1.61; 95% confidence interval (CI), 1.23–2.10; P ¼ 0.001]. Diabetes was associated with
nonfatal AMI (HR, 1.68; 95% CI, 1.23–2.31; P ¼ 0.001) but not with fatal AMI (HR, 1.42; 95% CI, 0.88–2.28;
P ¼ 0.146). Hazard ratios (95% CIs) for the association of diabetes with all-cause mortality, cardiovascular mortality,
all-cause hospitalization, and cardiovascular hospitalization were 1.12 (0.93–1.37; P ¼ 0.224), 1.11 (0.90–1.37;
P ¼ 0.318), 1.13 (1.00–1.27; P ¼ 0.054), and 1.20 (1.01–1.44; P ¼ 0.042), respectively.
Conclusion In post-AMI patients with systolic HF, diabetes mellitus is a significant independent risk factor for recurrent short-
term nonfatal AMI, but had no association with fatal AMI.
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Introduction
Diabetes mellitus is a risk factor for acute myocardial infarction
(AMI).1– 3 Although the associations between diabetes and out-
comes after AMI have been studied previously, the association of dia-
betes on recurrent AMI in a large cohort of post-AMI patients with
systolic heart failure (HF) has not been well studied.4,5 Further,
associations between diabetes and poor outcomes have often
been attributed to older age and higher prevalence of cardiovascular
risk factors among those with diabetes. To what extent diabetes
has an independent association with poor outcomes in post-AMI
patients, however, is unclear. Traditional regression-based multivari-
able risk adjustment models may be limited by lack of procedural
transparency, concerns for residual bias, and strong and often unten-
able model assumptions.6 Propensity score matching, on the other
hand, can be used to assemble cohorts in which patients are balanced
on all measured baseline covariates and investigators are blinded to
study outcomes.7 – 13 Therefore, the objective of the current study
was to examine the association of diabetes with outcomes in a
propensity-matched cohort of post-AMI patients with systolic HF
in which those with and without diabetes would be well-balanced
on all measured baseline covariates.
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Methods
Source of study data
The Eplerenone Post-Acute Myocardial Infarction Heart Failure Effi-
cacy and Survival Study (EPHESUS) was a multicentre, international
(37 countries), randomized, double-blind, placebo-controlled clinical
trial that randomized 6632 patients with AMI complicated by symp-
toms of HF and left ventricular ejection fraction ≤40% between
27 December 1999, and 31 December 2001 to receive eplerenone
25–50 mg daily or placebo.14 These patients were receiving standard
medical therapy, including angiotensin-converting enzyme inhibitors
or angiotensin receptor blockers, beta-blockers, and coronary reperfu-
sion therapies. The details of the design and results of the EPHESUS
trial have been previously reported.14 Patients with a serum creatinine
.2.5 mg/dL or a potassium .5.0 mEq/L were excluded. An original
copy of the EPHESUS data was obtained from Pfizer Inc., which was
also the sponsor of the trial. However, Pfizer played no role in the
design, analysis, and interpretation of the study data.
History of diabetes mellitus
Data on history of diabetes mellitus was collected by study investi-
gators at baseline based on a physician diagnosis of diabetes. Although
baseline data on random plasma glucose was collected, there was no
data on baseline fasting plasma glucose. Of the 6632 EPHESUS partici-
pants, 2142 (32%) patients had a history of diabetes.
Study outcomes
For the current analysis, our main outcomes of interest were three
AMI related endpoints: incident recurrent fatal or nonfatal AMI, mor-
tality due to AMI, and hospitalization due to AMI during 2.5 years of
follow-up (median, 16 months and range, 0.3–30.42 months). Incident
AMI was confirmed using two of three usual criteria: (i) electrocardio-
graphic changes including ST-segment elevation, new Q waves, or both
for transmural AMI, and T-wave inversion, ST-segment depression, or
both for subendocardial AMI, (ii) typical symptoms, or (iii) elevation of
cardiac biochemical markers. Definite AMI (including silent AMI) was
diagnosed by unequivocal electrocardiographic evidence of a new MI
with or without a typical history, or a typical increase and decrease
in biochemical markers of myocardial damage in which the maximal
value reached was greater than twice the upper limit of the hospital
range for creatine kinase, or in which the creatine kinase-MB fraction
value was ≥10% of the creatine kinase value with either a typical
history, new equivocal changes on electrocardiogram, or both, indicat-
ing the presence of ischaemia; or elevation of troponin to over three
times the upper limit of the normal range of laboratory values. Acute
myocardial infarction related to a cardiac procedure was diagnosed by
a typical increase and decrease in biochemical markers of myocardial
damage in which the maximal value reached within 1 week is more
than three times the upper limit of the hospital range for creatine
kinase after catheterization or percutaneous transluminal coronary
angioplasty or greater than five times the upper limit of the hospital
range for CK after cardiac surgery. A death was considered to be
due to AMI if it occurred within 28 days after AMI, or when the occur-
rence of AMI and/or the date of occurrence of AMI were uncertain,
the primary cause of death was confirmed by autopsy to be AMI.
Among the 2238 matched patients, a total of 223 (10%) patients had
fatal or nonfatal incident AMI, 163 (7%) patients had hospitalization
due to nonfatal AMI, and 70 (3%) patients had fatal AMI. None of
the 163 patients died during hospitalization for AMI. However, of
the 163 patients with nonfatal AMI, 40 (25%) patients subsequently
died from all causes, of which 10 were due to recurrent AMI. We
also examined other major natural history endpoints including mor-
tality and hospitalization due to all causes and cardiovascular causes.
The cause of death or the primary diagnosis leading to hospitalization
was adjudicated by an EPHESUS critical-events committee, members
of which were blinded to the patient’s study drug assignment.
Assembly of a balanced cohort
Because of the imbalances in baseline covariates between patients with
and without diabetes, we used propensity score matching to assemble a
cohort, in which those with and without diabetes would be well-balanced
on all measured baseline covariates.7–13 The propensity score for dia-
betes for a patient is that patient’s probability of having diabetes given
his/her measured baseline characteristics. We estimated propensity
scores for diabetes for each patient using a non-parsimonious multivari-
able logistic regression model. In the model, diabetes was the dependent
variable and 64 clinically relevant baseline characteristics (Figure 1) were
used as covariates.7–11 Using a greedy matching protocol, we attempted
to match each patient with diabetes with another patient without diabetes
who had a similar propensity score. In five repeated steps, patients were
matched by propensity scores to five, four, three, two, and one decimal
places, the details of which have been described elsewhere.7–11 In all,
we were able to match 1119 pairs of patients with and without a
history of diabetes with similar propensity for diabetes.
Because propensity score models are sample-specific adjusters and
are not intended to be used for out-of-sample prediction or estimation
of coefficients, measures of fitness and discrimination are not impor-
tant for assessment of the model’s effectiveness.7– 11,15,16 Instead, the
reduction in baseline covariate imbalance is a better marker of the effi-
cacy of a propensity score model, which is best assessed by estimating
absolute standardized differences. Absolute standardized differences
directly quantify the bias in the means (or proportions) of baseline
covariates across the groups and are expressed as a percentage of
the pooled standard deviations. Therefore, to quantify pre-match
imbalances and post-match balances, we calculated pre- and post-
match absolute standardized differences and presented those findings
as Love plots.8,11 An absolute standardized difference of 0% indicate no
residual bias and ,10% is considered of inconsequential bias.
Assembly of a pre-match cohort of similar
sample size
To ensure that the post-match comparisions between patients with
and without diabetes were not affected by the smaller sample size
of the matched cohort, we assembled a pre-match cohort of the
same sample size as that of the matched cohort. This was done by
first identifying the 1119 patients with diabetes in the matched
cohort. Then, we identified a random sample of 1119 patients
without diabetes from the entire pre-match sample of 4490 patients
without diabetes. Finally, we linked these two data sets, thus assem-
bling a cohort of 1119 pairs of patients with and without diabetes.
Statistical analysis
For descriptive analyses, we used Pearson Chi-square and Wilcoxon
rank-sum tests for the pre-match, and McNemar’s test and paired
sample t-test for the post-match comparisons of baseline covariates
between patients with and without diabetes, as appropriate. We
used Kaplan–Meier plots and matched Cox-regression analysis to esti-
mate associations of a history of diabetes with outcomes during 2.5
years of follow-up. Log-minus-log scale survival plots were used to
check proportional hazards assumptions. We then repeated our analy-
sis in the pre-match cohort of 2238 patients. We performed subgroup
analyses to determine whether the association between diabetes and
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recurrent fatal or nonfatal AMI was homogenous across various sub-
groups of matched patients. All statistical analyses were completed
using SPSS for Windows, Rel. 15, 2006 (SPSS Inc., Chicago, IL, USA)
and two-sided tests with a P-value , 0.05 were considered significant.
Sensitivity analysis
Despite excellent balance between matched patients with and without
diabetes on all measured baseline covariates, confounding due to unmea-
sured covariates is still a possibility, as in all observational studies. A
formal sensitivity analysis using Rosenbaum’s formulation was conducted
to quantify the degree a hidden bias that would need to be present to
invalidate any conclusions based on significant associations between
diabetes and primary outcomes among our matched patients.17
Results
Baseline characteristics
Matched patients had a mean age of 66 (+11) years, 31% were
women and 10% were nonwhites. Before matching, patients with
diabetes were older, had a higher prevalence of women, and a
higher burden of cardiovascular comorbidities than those
without diabetes. These and other imbalances in baseline charac-
teristics between patients with and without diabetes were well-
balanced after matching so that no significant differences remained
(Table 1). Post-match absolute standardized differences for all
measured covariates were ,10% (most were ,5%), suggesting
substantial covariate balance across the groups (Figure 1).
Diabetes and recurrent fatal and nonfatal
acute myocardial infarction
Fatal and nonfatal AMI occurred in 136 (12%) and 87 (8%) patients,
respectively, with and without a history of diabetes [hazard ratio
(HR) when diabetes was compared with no diabetes, 1.61; 95%
confidence interval (CI), 1.23–2.10; P ¼ 0.001; Figure 2A and
Table 2]. In the absence of hidden bias, a sign-score test for
matched data with censoring provides evidence (P ¼ 0.003) that
patients with a history of diabetes clearly had more incident fatal
and nonfatal AMI than those without a history of diabetes. Our
sensitivity analysis suggests that a hidden binary covariate, which
is a near-perfect predictor of incident fatal and nonfatal AMI,
would need to increase the odds of diabetes by 17% to potentially
explain away this association. The results of our subgroup analyses
demonstrated that a history of diabetes had, in general, a hom-
ogenous association with fatal and nonfatal AMI across a wide
spectrum of patients (Figure 3).
Nonfatal AMI occurred in 101 (9%) and 62 (3%) patients,
respectively, with and without a history of diabetes (HR, 1.68;
95% CI, 1.23–2.31; P ¼ 0.001; Figure 2B and Table 2). A history
of diabetes was not associated with fatal AMI (HR, 1.42; 95% CI,
0.88–2.28; P ¼ 0.146; Figure 2C and Table 2). Among the 2238
random-pair patients, diabetes was significantly associated with
fatal and nonfatal AMI (HR, 1.73; 95% CI, 1.31–2.27; P , 0.001),
nonfatal AMI (HR, 1.73; 95% CI, 1.26–2.37; P , 0.001), and fatal
AMI (HR, 2.00; 95% CI, 1.18–3.38; P ¼ 0.010).
Figure 1 Love plots for absolute standardized differences for covariates between patients with and without a history of diabetes mellitus,
before and after propensity score matching. AMI, acute myocardial infarction; ACE, angiotensin-converting enzyme.
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Table 1 Baseline patient characteristics by a history of diabetes mellitus before and after propensity matching














Age, years 63 (+12) 66 (+10) ,0.001 66 (+12) 66 (+10) 0.505
Women 300 (27) 339 (30) 0.068 359 (32) 339 (30) 0.375
Non-white race 110 (10) 110 (12) 1.000 123 (11) 110 (10) 0.413
Smoking status
Current 405 (36) 270 (24) ,0.001 266 (24) 270 (24) 0.988
Never 411 (37) 495 (44) 502 (45) 495 (44)
Former 303 (27) 354 (32) 351 (31) 354 (32)
Duration of index AMI
hospitalization, days
15.2 (+8.3) 15.3 (+8.7) 0.795 15.2 (+8.6) 15.3 (+8.7) 0.686
Index AMI with ST elevation 833 (74) 736 (66) ,0.001 735 (66) 736 (66) 1.00
Time from index AMI to
randomization, days
7 (+3) 7 (+3) 0.774 7 (+3) 7 (+3) 0.697
Reperfusion or revascularization
therapy within 14 days of index
AMI
CABG 11 (1) 10 (1) 0.826 11 (1) 10 (1) 1.00
PCI 257 (23) 256 (23) 0.960 255 (23) 256 (23) 1.00
Thrombolysis 332 (30) 258 (23) ,0.001 251 (22) 258 (23) 0.759
Past medical history
AMI 280 (25) 338 (30) 0.006 342 (31) 338 (30) 0.890
Angina pectoris 433 (39) 497 (44) 0.006 517 (46) 497 (44) 0.415
Heart failure 140 (13) 211 (19) ,0.001 210 (19) 211 (19) 1.00
Heart failure hospitalization 71 (6) 107 (10) 0.005 120 (11) 107 (10) 0.393
Hypertension 635 (57) 746 (67) ,0.001 764 (68) 746 (67) 0.440
Medications
Eplerenone 569 (51) 561 (50) 0.735 594 (53) 561 (50) 0.163
ACE-inhibitors 943 (84) 961 (86) 0.286 974 (87) 961 (86) 0.463
Angiotensin-receptor blocker 40 (4) 41 (4) 0.910 44 (4) 41 (4) 0.828
Beta-blockers 826 (74) 830 (74) 0.847 811 (73) 830 (74) 0.388
Nitrates 687 (61) 699 (63) 0.601 706 (63) 699 (63) 0.795
Aspirin 993 (89) 978 (87) 0.328 984 (88) 978 (87) 0.750
Anti-platelet drugs 314 (28) 312 (28) 0.925 309 (28) 312 (28) 0.926
Anticoagulants 187 (17) 177 (16) 0.567 173 (16) 177 (16) 0.861
Statins 506 (45) 535 (48) 0.219 507 (45) 535 (48) 0.240
Digoxin 160 (14) 204 (18) 0.012 199 (18) 204 (18) 0.824
Loop diuretics 592 (53) 672 (60) 0.001 684 (61) 672 (60) 0.628
Calcium channel blockers 167 (15) 189 (17) 0.204 189 (17) 189 (17) 1.00
Anti-arrhythmic drugs 135 (12) 147 (13) 0.445 150 (13) 147 (13) 0.900
Killip status
I 105 (9) 218 (20) ,0.001 236 (21) 218 (20) 0.857
II 813 (73) 662 (59) 644 (58) 662 (59)
III 163 (15) 200 (18) 196 (18) 200 (18)
IV 38 (3) 39 (4) 43 (4) 39 (4)
Body mass index, kg/m2 26.9 (+4.2) 27.9 (+4.2) ,0.001 28.1 (+4.8) 27.9 (+4.2) 0.544
Systolic blood pressure, mmHg 118 (+16) 121 (+17) ,0.001 121 (+17) 121 (+17) 0.727
Diastolic blood pressure, mmHg 72 (+10) 72 (+11) 0.112 72 (+11) 72 (+11) 0.758
Pulse, bpm 74 (+11) 75 (+12) 0.053 75 (+12) 75 (+12) 0.653
Laboratory values
Continued
P.C. Deedwania et al.554
Diabetes and other outcomes
The presence of a history of diabetes had significant unadjusted
associations with nearly all outcomes among the 2238 random-
pair pre-match cohort (Table 3). However, among the 2238
balanced matched cohort, diabetes was only associated with
increased risk of cardiovascular hospitalizations and held a bor-
derline association with all-cause hospitalization. Pre- and post-
match associations between diabetes and other outcomes are
displayed in Table 3.
Diabetes and the effect of eplerenone
Among the pre-match 6632 EPHESUS participants, fatal or nonfatal
AMI occurred in 293 (9%) and 313 (9%) patients in the eplerenone
and placebo groups, respectively (HR when eplerenone was com-
pared with placebo, 0.92; 95% CI, 0.79–1.08; P ¼ 0.312; data not
shown). As previously reported by the EPHESUS investigators,
the effect of eplerenone on mortality did not vary by the presence
or absence of diabetes at baseline.14,18
Discussion
Findings of the current analysis demonstrate that in post-AMI
patients with systolic HF, a history of diabetes was associated
with increased risk of recurrent fatal or nonfatal AMI, which was
primarily driven by an increase in nonfatal AMI. Diabetes was
also associated with cardiovascular hospitalization, but had no
independent association with all-cause or cardiovascular mortality.
To the best of our knowledge, this is the first report of an associ-
ation between diabetes and recurrent AMI in a propensity-
matched cohort of post-AMI patients with systolic HF. These
findings provide important insights into the early effects of diabetes
after AMI suggesting that nonfatal AMI may be the first major clini-
cal cardiovascular manifestation after an index AMI in patients with
diabetes. While there was no increase in fatal AMI or cardiovascu-
lar mortality in the diabetes group, it is likely that an excess of
nonfatal AMI would over time result in progressive adverse left
ventricular remodelling with ensuing worsening of left ventricular
dysfunction leading to progressive chronic HF and associated
morbidity and mortality.
Figure 2 Kaplan–Meier plots for recurrent acute myocardial infarction (AMI) by a history of diabetes mellitus (DM): (A) fatal or nonfatal,
(B) nonfatal, and (C) fatal. CI, confidence interval; HR, hazard ratio.
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Table 1 Continued














Sodium, mEq/L 140 (+4) 140 (+4) 0.059 139 (+4) 140 (+4) 0.765
Potassium, mEq/L 4.27 (+0.44) 4.25 (+0.45) 0.288 4.25 (+0.45) 4.25 (+0.45) 0.849
Creatinine, mg/dL 1.14 (+0.31) 1.16 (+0.35) 0.184 1.16 (+0.35) 1.16 (+0.35) 0.854
Glucose, mg/dL 111 (+33) 135 (+52) ,0.001 134 (+71) 135 (+52) 0.382
Albumin, g/dL 3.73 (+0.62) 3.67 (+0.57) 0.016 3.7 (+0.6) 3.7 (+0.6) 0.964
Haemoglobin, g/dL 13.3 (+1.7) 13.3 (+1.8) 0.505 13 (+2) 13 (+2) 0.277
Left ventricular ejection
fraction, %
33.1 (+ 5.9) 32.3 (+ 6.2) 0.152 32.7 (+6.1) 32.8 (+6.2) 0.669
ACE, angiotensin converting enzyme; AMI, acute myocardial infarction, CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention.
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There are two potential explanations of the significant associ-
ations of diabetes with recurrent AMI in our balanced cohort of
matched patients: residual confounding by measured covariates
and cofounding due to unmeasured covariates. Because our
matched patients were balanced on 64 baseline characteristics,
they are unlikely to explain the observed associations. However,
Figure 3 Association of a history of diabetes mellitus with subsequent fatal or nonfatal myocardial infarction in subgroups of patients. CI,
confidence interval; HR, hazard ratio.
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Table 2 Association of a history of diabetes mellitus and recurrent acute myocardial infarction (AMI)









Before matching (n ¼ 1119) (n ¼ 1119)
Fatal or nonfatal AMI 83 (7) 136 (12) +5 1.73 (1.31–2.27) ,0.001
Nonfatal AMI 62 (6) 101 (9) +3 1.73 (1.26–2.37) 0.001
Fatal AMI 21 (2) 41 (4) +2 2.00 (1.18–3.38) 0.010
After matching (n ¼ 1119) (n ¼ 1119)
Fatal or nonfatal AMI 87 (8) 136 (12) +4 1.61 (1.23–2.10) 0.001
Nonfatal AMI 62 (6) 101 (9) +3 1.68 (1.23–2.31) 0.001
Fatal AMI 29 (3) 41 (4) +1 1.42 (0.88–2.28) 0.146
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it is possible that these characteristics may have changed during
follow-up thus increasing the risk of subsequent AMI in those
with diabetes.19–22 Findings from our sensitivity analysis suggest
that the association between diabetes and recurrent AMI was
rather insensitive to an unmeasured binary confounder. The lack
of an intrinsic association between diabetes and fatal AMI is
likely due to a relatively small number of events and/or short
follow-up of the EPHESUS trial. However, diabetes also had no
intrinsic association with all-cause or cardiovascular mortality,
despite much higher event rates for those outcomes, suggesting
that the early effect of diabetes may not be fatal in nature.
The association between diabetes and recurrent nonfatal AMI may
be a direct effect of diabetes. The metabolic effect of diabetes on car-
diovascular morbidity and mortality is complex.23–26 Diabetes is
associated with activation of the renin–angiotensin–aldosterone
system.23,24 Collagen cross-linking is a major mechanism by which vas-
cular and cardiac compliance is diminished in diabetes and may also
contribute to diabetic cardiomyopathy.25,26 Other potential under-
lying mechanisms may include accelerated atherosclerosis associated
with diabetes. Hyperglycaemia, insulin resistance, and advanced glyca-
tion end-products have been implicated in vascular inflammation and
endothelial dysfunction in patients with diabetes.27 Further important
contributing factors may include increased platelet activation, pres-
ence of a chronic hypercoagulable state, and impaired fibrinoly-
sis.28–30 Serum levels of insulin-like growth factor-binding protein-1
are elevated in patients with diabetes, which in turn has been
shown to be associated with increased risk for cardiovascular mor-
tality and morbidity in these patients.19
Studies of associations between a history of diabetes and out-
comes after AMI are limited by relatively small sample size and
failure to account for various important cardiovascular comorbid-
ities and risk factors, including hyperglycaemia and hyperlipidae-
mia.2– 5,31– 34 Further, only a few of these studies examined the
association between diabetes and recurrent AMI.4,5 In the Framing-
ham Heart Study, of the 609 patients who survived an initial AMI,
92 had a history of diabetes and the age-adjusted incidence rates of
recurrent AMI for participants with and without diabetes were
approximately 650 and 400 per 10 000 person-years, respectively.4
Findings from the Finnish Social Insurance Institution registry data
suggest that of the 238 post-AMI patients, 169 had a history of dia-
betes and the unadjusted incidence rates of recurrent fatal and
nonfatal AMI for participants with and without diabetes were
780 and 300 per 10 000 person-years, respectively.5 In contrast
to these studies, our study is distinguished by its contemporary
nature, the presence of baseline systolic HF, larger sample size,
the use of propensity-matched design to assemble a cohort that
was balanced on 64 baseline covariates.
The findings of the current analysis are important as they
help identify a subset of post-AMI patients who are at increased
risk of subsequent nonfatal AMI. We observed that
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Table 3 Effects of a history of diabetes on all other outcomes in EPHESUS









Before matching (n ¼ 1119) (n ¼ 1119)
All-cause death 148 (13) 212 (19) +6 1.50 (1.21–1.85) 0.001
Cardiovascular death 129 (12) 182 (16) +4 1.47 (1.17–1.84) 0.001
Heart failure death 34 (3) 50 (5) +2 1.54 (1.00–2.38) 0.052
Sudden cardiac death 52 (5) 68 (6) +1 1.37 (0.95–1.96) 0.089
All-cause hospitalization 494 (44) 554 (50) +6 1.19 (1.06–1.35) 0.004
Cardiovascular hospitalization 190 (17) 263 (24) +7 1.49 (1.23–1.79) ,0.001
Heart failure hospitalization 104 (9) 164 (15) +6 1.67 (1.31–2.13) ,0.001
Cardiovascular hospitalization
or cardiovascular death
283 (25) 374 (33) +8 1.42 (1.21–1.65) ,0.001
All-cause hospitalization or all-cause death 578 (52) 650 (58) +6 1.20 (1.07–1.34) 0.002
After matching (n ¼ 1119) (n ¼ 1119)
All-cause death 191 (17) 212 (19) +2 1.12 (0.93–1.37) 0.224
Cardiovascular death 166 (15) 182 (16) +1 1.11 (0.90–1.37) 0.318
Heart failure death 47 (4) 50 (5) +1 1.09 (0.73–1.62) 0.678
Sudden cardiac death 71 (6) 68 (6) +0 0.97 (0.70–1.36) 0.867
All-cause hospitalization 506 (45) 554 (50) +5 1.13 (1.00–1.27) 0.054
Cardiovascular hospitalization 225 (20) 263 (24) +4 1.20 (1.01–1.44) 0.042
Heart failure hospitalization 150 (13) 164 (15) +2 1.10 (0.89–1.38) 0.382
Cardiovascular hospitalization
or cardiovascular death
349 (31) 374 (33) +2 1.10 (0.95–1.27) 0.198
All-cause hospitalization or all-cause death 618 (55) 650 (58) +3 1.08 (0.97–1.21) 0.169
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diabetes-associated increased risk of recurrent AMI was higher in
those not receiving beta-blockers and without coronary revascu-
larization. The use of these therapies may explain the relatively
low incidence of fatal AMI in our study. In the Framingham
Heart Study, of the 609 patients who survived an initial AMI, 92
had a history of diabetes and the age-adjusted incidence rates of
recurrent AMI for participants with and without diabetes were
724 and 326 per 10 000 person-years, respectively.4 In contrast,
the incidence rates for recurrent fatal AMI for matched patients
with and without diabetes in our study were 291 and 200 per
10 000 person-years, respectively. Eplerenone has been shown
to reduce adverse cardiovascular events in diabetes,18 and may
help improve long-term prognosis in these patients.
Our study has several limitations. We used a history of diabetes
and the diagnosis of diabetes was not centrally adjudicated. Simi-
larly, patients without diabetes at baseline may have developed dia-
betes during follow up, which may have led to regression dilution
and underestimation of true association.35 We also had no data on
the duration, type, or control status of diabetes. The findings of the
current study based on post-AMI patients with systolic HF may not
be generalized to post-AMI patients without systolic HF.
In conclusion, in post-AMI patients with systolic HF receiving
standard therapy, diabetes is a marker of poor outcomes. Although
diabetes was independently associated with increased risk of recur-
rent nonfatal AMI during over 2 years of follow-up, there was no
independent association with AMI mortality. Whether a more
aggressive control of diabetes may reduce the risk of recurrent
AMI in these patients is unknown and needs to be prospectively
determined by future studies.
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